As access to Sayana® Press (subcutaneous depot medroxyprogesterone acetate, or DMPA-SC in Uniject™) expands globally, PATH has monitored product consumption in four pilot introduction countries: Burkina Faso, Niger, Senegal, and Uganda. As the introduction phase draws to a close and all four countries move toward scale-up, they are transitioning Sayana Press consumption data collection into national information systems.

Highlights of monitoring data for the full pilot period (July 2014–June 2016) include:

• More than 490,300 doses of Sayana Press were administered in Burkina Faso, Niger, Senegal, and Uganda.
• PATH estimates that Sayana Press was administered to more than 120,000 women using modern family planning for the first time.
• Niger administered the highest proportion of Sayana Press to new users, with just less than half of all doses going to first-time users of modern contraception. Sayana Press reaches a largely rural population in Niger, and the pilot represented the first time injectables were made available at the most peripheral level of the health system.
• Niger and Uganda administered the highest proportions of Sayana Press to women younger than 25 years—almost half of the total number of doses administered in each country.
• More information is available in this summary of PATH’s monitoring work and results. If you are interested in reading the full monitoring report, please email sayanapress@path.org. Full monitoring results from all four countries will be posted online in 2017.

*The small sample in Senegal is due to the sentinel site system established to gather data for certain indicators.